Edmond DE Rothschild Holding S.A. bought a new position in shares of AstraZeneca Plc (NYSE:AZN - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 454,062 shares of the company's stock, valued at approximately $74,081,000. AstraZeneca accounts for approximately 0.9% of Edmond DE Rothschild Holding S.A.'s investment portfolio, making the stock its 25th largest holding.
A number of other large investors also recently modified their holdings of AZN. Roxbury Financial LLC acquired a new position in shares of AstraZeneca in the 2nd quarter valued at about $29,000. Laurel Wealth Advisors LLC bought a new position in AstraZeneca in the third quarter worth about $30,000. GK Wealth Management LLC acquired a new position in AstraZeneca in the third quarter valued at approximately $31,000. Lynch Investment Planning LLC acquired a new position in AstraZeneca in the third quarter valued at approximately $32,000. Finally, Resources Management Corp CT ADV acquired a new position in AstraZeneca in the first quarter valued at approximately $35,000. 20.35% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Weiss Ratings upgraded AstraZeneca from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday, October 26th. Nordea Equity Research upgraded AstraZeneca from a "sell" rating to a "buy" rating in a research report on Tuesday, October 13th. Deutsche Bank upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research note on Tuesday, September 15th. Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded AstraZeneca from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $206.67.
Check Out Our Latest Research Report on AZN
AstraZeneca Stock Performance
Shares of NYSE AZN opened at $175.34 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The stock has a 50 day simple moving average of $170.44 and a 200-day simple moving average of $180.08. The company has a market cap of $271.94 billion, a PE ratio of 24.80, a P/E/G ratio of 1.39 and a beta of 0.24. AstraZeneca Plc has a 12-month low of $153.41 and a 12-month high of $212.71.
AstraZeneca (NYSE:AZN - Get Free Report) last announced its earnings results on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.19. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The firm's revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.38 EPS. On average, equities research analysts forecast that AstraZeneca Plc will post 10.22 EPS for the current year.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.